Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Zenta Walther"'
Autor:
Daniel S. Lenchner, Zaritza O. Petrova, Lisa Hunihan, Kumar D. Ashtekar, Zenta Walther, Frederick H. Wilson
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-10 (2024)
Abstract EGFR tyrosine kinase inhibitors (TKIs) have transformed the treatment of EGFR-mutated non-small cell lung carcinoma (NSCLC); however, therapeutic resistance remains a clinical challenge. Acquired secondary EGFR mutations that increase ATP af
Externí odkaz:
https://doaj.org/article/df24accd246b45819fd7a53ffc9348ab
Autor:
Iris K. van Alderwerelt van Rosenburgh, David M. Lu, Michael J. Grant, Steven E. Stayrook, Manali Phadke, Zenta Walther, Sarah B. Goldberg, Katerina Politi, Mark A. Lemmon, Kumar D. Ashtekar, Yuko Tsutsui
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-16 (2022)
Although small molecule tyrosine kinase inhibitors are effective in lung cancer driven by mutated EGFR, some receptor variants fail to respond. Here, the authors identify structural features of an important set of EGFR variants with reduced inhibitor
Externí odkaz:
https://doaj.org/article/b04886b84f654ae4b677dfc2b5e44cc2
Publikováno v:
Human Pathology: Case Reports, Vol 15, Iss , Pp 95-98 (2019)
Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells is a rare pancreatic tumor of unclear origin. This case reports a 72-year-old male with bloating and indigestion for about six years who was found to have a 5 cm laterally sp
Externí odkaz:
https://doaj.org/article/d71f2a4c18864a14b73b7f7356488946
Autor:
Valentina Pirazzoli, Caroline Nebhan, Xiaoling Song, Anna Wurtz, Zenta Walther, Guoping Cai, Zhongming Zhao, Peilin Jia, Elisa de Stanchina, Erik M. Shapiro, Molly Gale, Ruonan Yin, Leora Horn, David P. Carbone, Philip J. Stephens, Vincent Miller, Scott Gettinger, William Pao, Katerina Politi
Publikováno v:
Cell Reports, Vol 7, Iss 4, Pp 999-1008 (2014)
Patients with EGFR-mutant lung adenocarcinomas (LUADs) who initially respond to first-generation tyrosine kinase inhibitors (TKIs) develop resistance to these drugs. A combination of the irreversible TKI afatinib and the EGFR antibody cetuximab can b
Externí odkaz:
https://doaj.org/article/86956aaf1ede481dad5ccf05981d0a99
Autor:
Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer, Iris K. van Alderwerelt van Rosenburgh, Anna Wurtz, Andrew J. Piper-Valillo, Zofia Piotrowska, Christina Falcon, Helena A. Yu, Charu Aggarwal, Dylan Scholes, Tejas Patil, Christina Nguyen, Manali Phadke, Fang-Yong Li, Joel Neal, Mark A. Lemmon, Zenta Walther, Katerina Politi, Sarah B. Goldberg
Publikováno v:
Clinical Cancer Research. 29:2123-2130
Purpose: The uncommon EGFR exon 19 deletion (ex19del), L747_A750>P, demonstrates reduced sensitivity to osimertinib compared with the common ex19del, E746_A750del in preclinical models. The clinical efficacy of osimertinib in patients with non–smal
Autor:
Philip C. Mack, Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick, Zenta Walther, Fred R. Hirsch, Katerina Politi, Karen Kelly, David R. Gandara
Publikováno v:
Clin Cancer Res
Purpose: Dynamic changes in circulating tumor DNA (ctDNA) are under investigation as an early indicator of treatment outcome. Experimental Design: Serial plasma ctDNA (baseline, 8 weeks, and at progression) was prospectively incorporated into the SWO
Autor:
Sarah B. Goldberg, Katerina Politi, Zenta Walther, Mark A. Lemmon, Joel Neal, Fang-Yong Li, Manali Phadke, Christina Nguyen, Tejas Patil, Dylan Scholes, Charu Aggarwal, Helena A. Yu, Christina Falcon, Zofia Piotrowska, Andrew J. Piper-Valillo, Anna Wurtz, Iris K. van Alderwerelt van Rosenburgh, Paul Stockhammer, Jacqueline H. Starrett, Jacqueline V. Aredo, Michael J. Grant
Supplementary Figure S3. Progression Free Survival for patients with tumors harboring select exon 19 deletions treated with second or later line osimertinib (T790M+). The point estimate for median progression free survival associated with each mutati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6212fa6eedce5e7e3c197a0dc1bfdad4
https://doi.org/10.1158/1078-0432.22651608
https://doi.org/10.1158/1078-0432.22651608
Autor:
Sarah B. Goldberg, Katerina Politi, Zenta Walther, Mark A. Lemmon, Joel Neal, Fang-Yong Li, Manali Phadke, Christina Nguyen, Tejas Patil, Dylan Scholes, Charu Aggarwal, Helena A. Yu, Christina Falcon, Zofia Piotrowska, Andrew J. Piper-Valillo, Anna Wurtz, Iris K. van Alderwerelt van Rosenburgh, Paul Stockhammer, Jacqueline H. Starrett, Jacqueline V. Aredo, Michael J. Grant
Purpose:The uncommon EGFR exon 19 deletion (ex19del), L747_A750>P, demonstrates reduced sensitivity to osimertinib compared with the common ex19del, E746_A750del in preclinical models. The clinical efficacy of osimertinib in patients with non–small
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4455ab4c1799ba13f63c8913712becae
https://doi.org/10.1158/1078-0432.c.6604893.v1
https://doi.org/10.1158/1078-0432.c.6604893.v1
Autor:
Sarah B. Goldberg, Katerina Politi, Zenta Walther, Mark A. Lemmon, Joel Neal, Fang-Yong Li, Manali Phadke, Christina Nguyen, Tejas Patil, Dylan Scholes, Charu Aggarwal, Helena A. Yu, Christina Falcon, Zofia Piotrowska, Andrew J. Piper-Valillo, Anna Wurtz, Iris K. van Alderwerelt van Rosenburgh, Paul Stockhammer, Jacqueline H. Starrett, Jacqueline V. Aredo, Michael J. Grant
Supplementary Table S1. Descriptive analysis of patient characteristics and outcomes for those with tumors harboring uncommon exon 19 deletions treated with osimertinib. Each variant represented ≤2.5% of the study cohort. Patients with + for “Smo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d11c6eb873c8463a1638764ea648a73
https://doi.org/10.1158/1078-0432.22651605.v1
https://doi.org/10.1158/1078-0432.22651605.v1
Autor:
Julian Downward, Katerina Politi, Egbert F. Smit, René Bernards, Harold Varmus, Marc Ladanyi, Yixuan Gong, Almudena García-Castaño, Javier Gómez-Román, Daniëlle A.M. Heideman, Guus J. Heynen, Anna Wurtz, Zenta Walther, Scott Gettinger, Mary Ann Melnick, Rebecca E. Saunders, Ming Jiang, Patricia H. Warne, Catherine Cowell, Elza C. de Bruin
PDF file 108K, Table S4. Clinical characteristics of human lung adenocarcinoma samples
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17fc1bd0ab84567b3626be4fede6e78f
https://doi.org/10.1158/2159-8290.22529726
https://doi.org/10.1158/2159-8290.22529726